A review on resistance to immune checkpoint inhibitors (ICIs) in NSCLC highlights the STK11/KEAP1 co-mutation subgroup as a significant challenge and TGF-beta as a promising therapeutic target. Separately, a multidisciplinary panel discussed the diagnosis and treatment of HER2-positive NSCLC, covering NGS and IHC testing, the evolving HER2-low/ultralow space, and therapies including T-DXd and the investigational agents zongertinib and sevabertinib.
“After resistance to ICIs, treatments become toxic and less effective. This is NOT one size fits all (Fig3). We will require multiple solutions for complex mechanisms of resistance.”
— @mgonzalezvelMD · ICI Resistance in NSCLC · View post ↗Two studies from the American Society of Breast Surgeons Annual Meeting presented new comparative outcome data to inform decision-making for breast cancer surgeries. Additionally, infographics are being shared that summarize the mechanisms of resistance, structural details of newer investigational antibody-drug conjugates (ADCs), and the timeline of past FDA approvals for ADCs in breast cancer.
“New data inform decision-making for breast cancer surgeries”
— @JournalCancer · Surgical Decision-Making · View post ↗
“Nice Infographics to Show 1-mechanism of resistance of ADCs used in Breast Cancer 2-structural details of Newer ADC being studied in Breast cancer 3- Timeline for approval of All ADCs by USA FDA in Breast cancer till date.”
— @SuyogCancer · ADCs in Breast Cancer · View post ↗The Phase 3 CLARITY-Gastric 01 trial showed the investigational anti-CLDN18.2 antibody-drug conjugate AZD0901 improved overall survival versus chemotherapy for patients with CLDN18.2-positive gastric or gastroesophageal junction cancer in the second-line or later setting. Separately, a Texas Registry analysis published in JAMA Oncology found that treatment delays and language barriers negatively impacted overall survival in early-age onset colorectal cancer, particularly in Latino patients.
“Excited to see the positive results from Phase 3 CLARITY-Gastric 01. AZD0901, an anti-CLDN18.2 ADC, improved OS vs 2nd or later-line chemo in patients with CLDN18.2+ gastric/GEJ cancer.”
— @KoheiShitara · CLDN18.2 ADC · View post ↗
“Texas Registry analysis reveals: Treatment Delays in Early Age–Onset #Colorectal #Cancer notably in #Latinos and the impact of a language barrier on overall survival.”
— @CathyEngMD · Colorectal Cancer Disparities · View post ↗“Where does histotripsy fit into hepatocellular carcinoma care?”
— @JournalCancer · Histotripsy in HCC · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
In muscle-invasive bladder cancer (MIBC), cisplatin remains the standard adjuvant therapy post-cystectomy for eligible patients, but future strategies are moving toward ctDNA guidance, with the IMvigor011 and MODERN trials anticipated to define the next steps. Separately, an automated volumetric iRECIST tool for metastatic kidney cancer response assessment on ipi/nivo nearly doubled interobserver agreement (κ from 0.34 to 0.67). New research also identified tertiary lymphoid structures in kidney cancer as reservoirs of tumor-specific T cells.
“Adjuvant therapy after cystectomy in MIBC: cisplatin remains standard for eligible patients with high-risk pathology. Two ICIs have shown meaningful DFS benefit. But the field is moving toward ctDNA-guided strategies. IMvigor011 and MODERN will define what comes next.”
— @drenriquegrande · Adjuvant MIBC Therapy · View post ↗
“Tertiary lymphoid structures in Kidney Cancer are reservoirs of tumor-specific T cells with stem-like progenitor features with an interplay with immunosuppressive macrophages that could be leveraged by T cell immunotherapies.”
— @DrChoueiri · Kidney Cancer Immunology · View post ↗
“Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy”
— @AndreaNecchi · Cystectomy Sparing in MIBC · View post ↗
“Response assessment in metastatic kidney cancer on ipi/nivo is hard: over half of patients show atypical patterns, and readers disagree. An automated volumetric iRECIST tool nearly doubled reader agreement.”
— @katy_beckermann · RCC Response Assessment · View post ↗Data from the GEM trials in newly diagnosed multiple myeloma (NDMM) shows that MRD trajectory over time, not a single measurement, is the key prognostic factor; patients who were initially MRD-positive but achieved late sustained negativity had a 6-year PFS of 81.5%. Other discussions highlighted a study of ASCT for POEMS syndrome showing a median PFS of 102.6 months, and a decade-old risk model for smoldering myeloma based on concurrent changes in M protein and hemoglobin.
“0.5 gm/dL increase in M protein occurring concurrently with 0.5 gm/dL drop in hemoglobin qualifies as high risk SMM with >80% risk of progression in 2 years.”
— @VincentRK · Smoldering Myeloma Risk · View post ↗
“27% of patients in the GEM trials were MRD+ on their first assessment and still landed at a 6-year PFS of 81.5%. That number should change how we talk to patients after a single positive test.”
— @kansagraMD · MRD Dynamics · View post ↗📌 Amplified by @KolPulseAI
“Study of ASCT for #POEMS syndrome finds heme response to 1st-line therapy in 77.5%, median PFS 102.6 months & OS 146.9 months, 5-year rates of 69.0% & 87.6%”
— @Myeloma_Doc · POEMS Syndrome · View post ↗A study using Global Burden of Disease (GBD) data for the East Asia region from 1990–2021 found a rising incidence but falling mortality for blood cancers. Separately, discussions at the National ICE-T Congress are focused on barriers to access and equity for CAR-T therapy as its use is explored beyond hematologic malignancies into solid tumors and immune-mediated diseases.
“CAR-T is changing what’s possible but who gets to benefit?”
— @zarabaloc · CAR-T Access & Equity · View post ↗
“Rising incidence, falling mortality — and one blood cancer surging fastest of all.”
— @TheCORGILab · Blood Cancer Epidemiology · View post ↗
“In AML, CLL and mantle cell lymphoma there are decisions where NCCN, ELN and iwCLL genuinely stop short, and two excellent clinicians can defend opposite choices.”
— @DrArturoAI · AI in Clinical Decision-Making · View post ↗📌 Amplified by @KolPulseAI